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Summary
Preterm labor is a public health problem and to this day, it’s the great challenge of modern obstetrics. We conducted a ran-
domized double-blind controlled study. At the admission, all patients were submitted to cardiotocography. Patients with 
regular contractions but without decreasing of cervical length or funneling at transvaginal sonography were admitted. 90 pa-
tients at 24-34 weeks of gestation were finally recruited. Patients were randomly divided in two groups: A group (45 patients) 
received a single transvaginal dose of docosahexaenoic acid (1 gr of DHA); B group (45 patients) received placebo. At 120 
minutes, cardiotocographic examination was performed in all patients. A group showed a significant decrease in number and 
intensity of contractions (p<0.05) as compared to B group. The results of our study show that vaginally administered DHA 
during pregnancy is effective on uterine contractions providing a significant decrease of spontaneous contractions and prob-
ably reducing the risk of preterm delivery.
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Introduction
Preterm labor is defined as regular uterine contractions re-
sulting in changes in the cervix that start between 24 weeks 
of pregnancy and 37 weeks of pregnancy. The preterm birth 
is the leading cause of perinatal mortality and morbidity, ac-
counting for 28% of neonatal mortality worldwide. Although 
the cause is often unknown, a variety of factors may play a 
role in preterm birth; inflammation is the most common and 
most important. Vaginal infections seem to play an impor-
tant role. Infections result in the activation of the inflamma-
tory cascade, which precedes and causes the shortening of the 
cervix. On this basis, we focused our studies on inflammatory 
mediators, including cytokines and chemokines, in women’s 
cervix [2]. The fatty acids are precursors of molecules such 
as prostaglandins, leukotrienes and thromboxanes: all these 
inflammatory mediators play a role in the pathophysiology 
of preterm birth [7]. The human body can produce the satu-
rated and monounsaturated fatty acids but cannot synthesize 
omega-3 and omega-6 polyunsaturated fatty acids (PUFA). 
The precursors of these two families- alpha linolenic acid 
(ALA) and linoleic acid (LA)- are called “essential”; LA and 
ALA are required in the diet [3,4]. Foods with a higher con-
tent of omega- fatty acids include salmon, mackerel, sar-
dines, herring, tuna, anchovies (blue fish). Dietary LA serves 
as the precursor for the n-6 series of polyunsaturated fatty 
acids (PUFAs) and dietary ALA is the precursor for the n-3 
PUFA series. ALA is converted to eicosapentaenoic acid 
(EPA) and then in docosahexaenoic acid (DHA), while LA 
is converted to arachidonic acid (AA). DHA is an essential 
component of cell membranes, where it modulates, together 
with the EPA, the right degree of fluidity and permeability. 
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The optimal omega-3/omega-6 fatty acids ratio is 1:5 whereas 
the western diet ranges from 10:1 to 25:1, fueling concern that 
this diet, characterized by low fish consumption, leads to a de-
cline of omega-3 PUFAs intake in favour of omega-6 PUFAs 
and to an altered omega-6/omega-3 ratio from 1:10 to 1:20, a 
so called pro-inflammatory ratio. In fact, omega-3 fatty acids 
are essential and can only be obtained from the diet [8]. The 
increased intake of omega-3 in proportion to other fats would 
result in the down-regulation of the synthesis of omega-6 and 
consequently the decreased production of pro-inflammatory 
cytokines [7].
The American Dietetic Association (ADA) with the Dietitians 
of Canada [2] recommend at least 500 mg/day of PUFAs for all 
healthy adults including pregnant and lactating women. The 
European Commission with the International Society for the 
Study of Fatty Acids and Lipids (ISSFAL) specifically recom-
mends that pregnant and lactating women consume a mini-
mum of 200 mg DHA per day [7,8]. These recommendations 
could be met by consuming 1 to 2 portions per week of fish 
with high content of omega-3 fatty acids, which is the recom-
mendation by Health Canada [8] and the United States Dietary 
Guidelines Advisory Committee for all women [4]. Since this 
considerations we evaluate the role of docosahexaenoic acid 
on uterine contractions to show if this molecule can be of use 
in reducing the early symptoms and signs of preterm delivery.
Materials and Methods
We conducted a randomized double-blind controlled study by 
February 2014 to November 2014. The study was conducted 
at the Reproductive Medicine Unit of the University of Naples 
Federico II. We enrolled 90 symptomatic patients between 24-
34 week of gestation, for threatened preterm labour. The study 
was approved by the Ethics Committee of the University Fed-
erico II (Protocol’s number 268/13). The patients underwent 
informed consent. The patients were divided into 2 groups ac-
cording to random criteria, 45 patients in the treatment group 
(A group) and 45 to the placebo group (B group). 140 pregnant 
patients with pelvic pain at 24-34 weeks were evaluated. At the 
admission patients were submitted to digital vaginal exami-
nation, transvaginal ultrasonography and cardiotocography 
(CTG). Only patients with regular contractions at CTG (4 in 
20 minutes or 8 in 60 minutes, lasting at least 30 seconds) (1) 
and without clinical or sonographic modifications of the cer-
vix were considered for the study.
The inclusion criteria were the following:
1. Caucasian women between 18 and 38 years of age
2. Singleton pregnancy
3. Uterine contractions reported
4. Regular uterine activity demonstrated to cardiotocography 
pattern (> 4 contractions in 20 minutes)
5. Cervical length > 25 mm and absence of funneling at trans-
vaginal ultrasound
6. Intact membranes
7. Obstetric history negative for preterm labor.
Patients with the following characteristics were excluded:
1. Maternal age < 18 and > 38
2. Multiple pregnancy
3. Cervical length < 25 mm and / or presence of funneling at 
transvaginal ultrasound
4. Infections of the genito-urinary tract (positive vaginal/urine 
culture)
5. Intra-amniotic infections, based on clinical and biochemical 
parameters: maternal temperature > 38°C, malodorous vaginal 
discharge, maternal leucocytosis (>15000 cell/mm3), maternal 
tachycardia (>100 beats/min), uterine tenderness
6. Pre-pregnancy or gestation pathologies (such as maternal 
autoimmune diseases, antiphospholipid syndrome, gestational 
hypertension, preeclampsia)
Finally, 90 patients were enrolled in the study. Patients were 
randomly allocated in the 2 group, the treatment group (A 
group) and the placebo group (B group) using computer-gen-
erated numbers in sealed envelopes (Figure 1).
The patients were randomized to receive a single vaginal 
capsule of docosahexaenoic acid (-Metra-medical device CE 
Class III produced by Pharmarte, registration number CE 
0373 containing fish oil rich in DHA - 1g) or vaginal placebo 
capsule. The placebo capsules were specially manufactured to 
look identical to the DHA capsules. The capsules were placed 
in sacs and then stored in envelopes numbered from 1 to 90. 
The envelopes were numbered and randomized according to 
computer-generated randomization tables to ensure an equal 
number of patients in each arm. Access to the randomization 
code was available only to the pharmacist who manufactured 
the placebo and packed the envelops and was not available to 
any of the treating physicians or patients. Patients were reval-
ued by cardiotocography pattern after 120 minutes after ad-
ministration of the preparation.
The primary endpoint was to determine the number of uterine 
contractions (<4 in 20 minutes or < 8 in 60 minutes) by tocog-
raphy after 120 minutes from vaginal administration of one 
gram of DHA.
Statistical analysis
Statistical analysis was performed using Graph Pad Prism 4.0 
software (Graph Pad Software Inc., La Jolla, CA). The t test was 
used for assessing the significance of the difference between 
continuous variables. The X2 test or the Fisher exact test was 
used to assess the statistical significance of categorical vara-
bles. Differences associated with p values lower than 0.05 were 
considered statistically significant. The results are reported as 
mean ± standard deviation (SD). A significant difference was 
found in terms of number of uterine contractions at CTG be-
tween the two groups (p< 0.05).
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Figure 1: Flow chart for the allocation of the patients.
 Results
In A group the mean number of contractions was significantly 
lower after the treatment (6.11±1.30 vs 3.13±3.33, p=0.0001) 
(Figure 2) while in B group the difference was not significant 
(5.28±1.32 vs 5.55±1.45, p=0.36) (Figure 3). Patients in A group 
showed a significant reduction in the mean number of contrac-
tions at cardiotocography after 120 minutes of docosahexaenoic 
acid somministration than in B group (3.13±3.33 vs 5.55±1.45, 
p=0.0001) (Figure 4). The number of patients with a reduction 
of uterine contractions was significantly higher in A group. In 
particular, in A group, 20 patients (44%) had no contractions 
at the post-treatment CTG, 11 patients (24%) had a reduction 
in the number of contractions (< 6 in 60 minutes); in 9 patients 
(20%) the number of contractions was unchanged and in 5 pa-
tients (11%) was detected worsening of symptoms. In B group, 
no patients showed improvement of symptoms, 28 patients 
(62%) presented an unchanged cardiotocographic pattern be-
fore and after the placebo, 15 patients (33%) showed worsening 
of the symptomatology and only 2 patients (5%) had a reduc-
tion in the number of contractions (Table 1).
Figure 2: Mean number of contractions before and after 
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Figure 3: Mean number of contractions before and after pla-
cebo (B group).
Figure 4: Mean number of contractions after treatment in A 
group e B group.
*** p 0.0001
Table 1: Effect of treatment on uterine contractions.
IncreasingUnchangedDecreasingNo contractionsFrequency of uter-
ine contractions
5 (11)9 (20)11 (24)20 (44)A group n=45
15 (33)28 (62)2 (5)0 (0)B group n=45
< 0.05<0.001< 0.05< 0.001P value
Data are presented as number of cases and percentage (%).
Discussion
Variation of dietary intake plays a key role in reducing some 
risks associated with pregnancy, such as risk of fetal and infant 
mortality, low birth weight [12,13] and premature births [2]. 
In this study, we observed that vaginally administered DHA 
during pregnancy acts on uterine contractions, in symptomat-
ic women resulting in muscle relaxation and induces disap-
pearance of spontaneous contractions in many cases. Several 
randomized controlled trials have shown that supplementa-
tion with omega-3 may influence the birth process by delaying 
the onset of labor, reducing the risk of recurrent preterm birth 
and in animal studies it seems to have a tocolytic effect [2,15].
The exact DHA’s mechanisms of action are not well under-
stood, the eicosanoid-mediated changes on myometrial con-
tractions and the connective tissue remodeling [5,12,15] seem 
involved. A high omega-6/omega-3 fatty acid ratio will result 
in increasing proinflammatory eicosanoid production; these 
metabolites have been associated with labor at term and pre-
term.
A higher intake of omega 3 fatty acids leads to a down-regula-
tion of the synthesis of omega-6 fatty acids and consequently 
reduces the production of prostaglandins responsible for cer-
vical changes in early labor. In additional, several studies have 
shown that DHA significantly reduces the secretion of IL-8 
and IL-6 from the amnion [2,7]. These cytokines are strongly 
associated with the onset of labor and this activity may con-
tribute to the ability of DHA, introduced by diet supplements, 
to prolong gestation and to decrease the risk of preterm de-
livery before 34 weeks. Animals with n-6 fatty acid deficiency 
and those fed with high dose of n-3 fatty acids have depressed 
prostaglandins synthesis and increased length of gestation [8]. 
Another possible effect on the duration of pregnancy could be 
linked to the disorganization of the electrical myometrial ac-
tivity: this could determine a delay in the onset of rhythmic 
and regular myometrial contractions [4].
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Several randomized controlled trials showed a reduction of 
preterm delivery with DHA supplementation during pregnan-
cy [6] n−3 supplementation was associated, compared to no 
supplementation in control subjects, with significantly greater 
duration of pregnancy [8]. The supplementation with marine 
oil in pregnancy is associated with a mean gestational age at 
delivery 2.6 days longer than women allocated placebo or no 
treatment and did have a lower risk of giving birth before 34 
completed weeks’ gestation compared with placebo [7].
Studies performed until today are based on the effects of oral 
administration of 200 mg omega-3 fatty acids, however, since 
oral administration is subject to hepatic metabolism and 
rapid inactivation, we hypothesized that the use of a vaginal 
formulation of DHA may provide a better bioavailability due 
to uterine-first-pass-effect, bypassing liver metabolism and 
directly reaching the cervix. Therefore, we evaluated the effi-
cacy of intravaginal formulation of 1gr of DHA, which, in fact, 
resulted in a more effective activity on myometrium than the 
oral one. Avoiding the first-pass effect, vaginal administration 
could have a more potent cervical action, with a reduction of 
omega 6 synthesis and consequent lower production of PGE2 
and PGF2α.
Conclusion
Maternal long-chain polyunsaturated fatty acids status, par-
ticularly docosahexaenoic acid (DHA), during pregnancy may 
influence maternal and infant outcomes [2,13]. Maternal life-
style and nutrition have long been recognized as important 
factors for both perinatal health and for the long-term health 
of the infant. Fish oil capsules are nearly devoid of mercury and 
other harmful compounds and can serve to augment omega-3 
fatty acids in the diet. The implications of DHA supplementa-
tion on fetal development, maternal outcomes and later infant 
growth is worth being elucidated and is promising in its poten-
tial for a positive impact on fetal and maternal outcomes [6].
The vaginal administration allows the use of dosage five times 
higher than the oral one, similar to the dosage tested in ani-
mal studies [3]. Furthermore, by passing the gastrointestinal 
absorption, DHA acts directly on the cervix and on the feto 
placental unit, contrasting hyperoxia [2]. Placental hyperoxia 
contributes to a persistent imbalance between pro-inflamma-
tory and anti-inflammatory mechanisms that leads to preterm 
birth and neonatal injuries [17]. The potential benefits of DHA 
intake (1 gr) in patients at risk of preterm birth should be con-
firmed and further studies are needed to evaluate the effects 
and effectiveness of long-term treatment with DHA.
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